Bold claim: Australia now has a permanent national public health backbone, and the road ahead is as much about unglamorous execution as it is about ambitious vision. But here’s where it gets controversial: how far the new Australian Centre for Disease Control (CDC) will actually transcend existing structures and deliver on broad expectations remains open to debate. This piece rephrases and clarifies the core ideas, expanding a bit with context to help beginners grasp the stakes and the trade-offs involved.
The first Director-General of the Australian Centre for Disease Control, Professor Zoe Wainer, is about to begin her role in a matter of weeks. In surveying the challenges ahead, Jason Staines argues that the CDC’s ability to become the trusted, coordinating hub envisaged by law will hinge not only on its internal capabilities but also on the engagement and strength of the communities it serves.
Professional associations, researchers, clinicians, consumer groups, and Aboriginal and Torres Strait Islander health leaders have helped shape the expectations surrounding the agency. They will also be the ones who judge whether those expectations are met. This matters especially now, as the broader public health infrastructure is under pressure: many organisations that contribute expertise, advocacy, and independent scrutiny face limited resources while demand and risk continue to grow.
Australia’s new national public health agency formally began operating as a standalone statutory authority on 1 January. This marks what many in the sector describe as a generational shift in how the country prepares for and responds to health threats.
The CDC has been created to fuse disease surveillance, expert analysis, and independent advice, all within a framework that requires transparency about the information it shares with governments. Its birth follows decades of advocacy from public health leaders and health organisations, sharpened by the COVID-19 pandemic and the subsequent inquiry, which recommended a permanent national body dedicated to prevention and control.
With legislation enacted, funding secured, and a Director-General appointed, attention is shifting from mere establishment to practical execution: what the CDC will prioritise, how quickly it can build capability, and whether it can meet the wide range of expectations placed upon it.
Calls for a national CDC stretch back at least to 1987, when epidemiologists warned about fragmented disease-control arrangements and uneven access to timely data. An interim centre began operating within the Department of Health and Aged Care in January 2024.
Legislation passed in late 2025 placed the permanent CDC on an independent statutory footing, backed by more than A$250 million over four years. The agency’s core functions include monitoring communicable and environmental threats, providing expert risk assessments, coordinating across jurisdictions, and issuing independent, evidence-informed advice. Transparency is embedded in the law: in most cases, the Director-General’s advice must be published alongside the underlying evidence.
One Health is a guiding frame for the CDC, acknowledging the interconnections between human, animal, and environmental systems. Its initial priorities cover communicable disease surveillance, pandemic preparedness, environmental health, and occupational respiratory conditions, with chronic disease slated for future consideration. However, the extent of the agency’s remit has been a point of contention during the legislative process. Some critics argued for a broader scope that would include chronic and non-communicable diseases; the final bill did not include these areas at launch, deferring them to a later review, potentially after an independent funding and operations assessment in 2028.
This staged approach means the early focus will be on infectious disease, environmental health, and emergency preparedness, with non-communicable diseases potentially expanding later. Some observers see this as a pragmatic start; others view it as a missed opportunity given rising risks from chronic conditions that affect population health.
First Nations leadership has remained a central question: how will Aboriginal and Torres Strait Islander leadership be integrated into the CDC’s work? Parliament debated whether the bill did enough to recognise structural drivers of Indigenous health. Proposals included expanding the definition of public health matters to explicitly include Indigenous health and social determinants, Indigenous data sovereignty principles, stronger representation, and a dedicated advisory committee. Those amendments were not adopted.
The Act does provide for representation through the agency’s Advisory Council, requiring the Minister to ensure at least one Council member is an Aboriginal person or Torres Strait Islander with relevant expertise. The Director-General is empowered to consult with Aboriginal and Torres Strait Islander organisations, including community-controlled bodies, and to tailor risk assessments with consideration for how different communities might be affected.
For some stakeholders, these provisions create a meaningful statutory foothold for partnership; for others, they stop short of deeper, formal arrangements proposed during debates. Yet many leaders in the community-controlled sector point to a collaborative ecosystem that has grown over recent years and is expected to continue under the CDC.
Dawn Casey of NACCHO notes that relationships among Aboriginal and Torres Strait Islander representatives and national decision-making bodies have deepened well before the CDC’s formal birth. She highlights the National Aboriginal and Torres Strait Islander Health Protection Committee, which brings together ACCHOs, state and territory governments, and chairs of national groups dealing with communicable diseases and tuberculosis. Casey argues that Indigenous voices have long influenced how advice is shaped, even if formal representation on the CDC’s central council remains a point of discussion. She emphasizes that the agency’s structure has potential, but acknowledges the need for extensive consultation to translate expectations into practice.
Professor Wainer, who assumes the Director-General role on 1 March, brings broad experience across clinical medicine, research, public health leadership, and government service. The medical community has welcomed her appointment as a strong leader capable of guiding the CDC’s early work, including lessons from the COVID-19 response.
On the global stage, confidence in pandemic preparedness is mixed. The World Health Organization has acknowledged progress in surveillance, laboratory networks, financing, and international cooperation, while warning that gains are fragile and uneven. The WHO urges governments not to deprioritise pandemic preparedness and prevention amid shifting funding toward defence and national security. Other observers note declining vaccination coverage, re-emergence of preventable diseases, and heightened political polarization around health measures. In this context, the CDC’s establishment signals a commitment to credible national institutions that can translate global intelligence into local action.
Even with legislation in place, the CDC’s practical boundaries were tested during its creation. Amendments seeking broader or sharper remit did not pass, but other changes were accepted. The law now requires annual reporting on Australia’s pandemic readiness and the health impacts of climate change, strengthening accountability while leaving room for future expansion.
Looking ahead, expectations from various stakeholders center on how the CDC will exercise authority and coordinate across levels of government, and how effectively it will translate evidence into policy and practice. Several submissions to the federal budget underscore a desire for stronger national leadership on data, surveillance, prevention, and workforce planning—areas that align with the agency’s legislated role, even if not always naming the CDC outright. The agency’s climate and environmental health mandate broadens its scope beyond infectious disease, positioning it within a growing international consensus that environmental change is a central determinant of health outcomes.
In short, the CDC sits at the intersection of policy, science, and community trust. Its credibility will be built not only through robust internal systems but also through the strength of the relationships it forges with governments, jurisdictions, and the communities it serves. And as the broader public health ecosystem contends with resource constraints and rising complexity, the CDC’s growth will be shaped by ongoing negotiations about evidence, trust, and accountability.
If you’d like a deeper dive into specific sections, I can break down the One Health implications, Indigenous leadership provisions, or the balance between infectious disease focus and potential expansion into chronic diseases with concrete examples.
Would you prefer a more detailed focus on the Indigenous leadership provisions and their practical implications, or a clearer, step-by-step timeline of the CDC’s expected milestones in its first two years?
